Aidan Crawley

Aidan has a background in finance and technology, both as an executive and founder. Previously worked in banking at Goldman Sachs and in Cleantech with Hazel Capital before moving to Silicon Valley to run Business Development for the fintech company Addepar.

With a deep interest in neuroscience and the role technology can play in delivering transformational outcomes, Aidan founded Amber Therapeutics in 2021 along with Tim Denison, Stefan De Wachter and Charles Knowles. Amber is developing the first adaptive neuromodulation therapy that is able to treat women suffering with mixed urinary incontinence.